{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:16:08Z","timestamp":1788318968560,"version":"build-2803163510"},"reference-count":156,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4033,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>\n                    Gatifloxacin is a new 8\u2014methoxy\u2010fluoroquinolone antibiotic approved for use in the United States in December 1999. It has a broad spectrum of activity with potent activity against gram\u2010positive bacteria, including penicillin\u2010resistant\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    , as well as excellent activity against gram\u2010negative and atypical organisms. Gatifloxacin is available in both oral and injectable forms and is administered once\/day. Bioavailability is 96%, with a plasma half\u2010life of approximately 8 hours in individuals with normal renal function. Elimination is primarily renal excretion of unchanged drug with no cytochrome P450\u2010mediated metabolism. The drug is distributed extensively into tissues and fluids and has a favorable pharmacodynamic profile against important pathogens. It had excellent efficacy in clinical studies of acute sinusitis, acute bacterial exacerbations of chronic bronchitis, community\u2010acquired pneumonia, complicated and uncomplicated urinary tract infections and pyelonephritis, skin and skin structure infections, and uncomplicated gonococcal infections. The agent is well tolerated, with no evidence of hepatic, cardiac, or phototoxicity noted thus far. Drug interactions are uncommon; however, like other fluoroquinolones, coadministration with multivalent cations should be avoided due to significantly decreased absorption. Gatifloxacin should prove to be a safe and effective agent for a wide variety of infections.\n                  <\/jats:p>","DOI":"10.1592\/phco.21.1.35.34440","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T12:07:51Z","timestamp":1086696471000},"page":"35-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Gatifloxacin, an Advanced 8\u2010Methoxy Fluoroquinolone"],"prefix":"10.1002","volume":"21","author":[{"given":"Douglas N.","family":"Fish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/AAC.42.10.2678","article-title":"Inhibitory activities of gatifloxacin (AM\u20101155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases","volume":"42","author":"Takei M","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.42.11.2978","article-title":"Fluoroquinolone action in mycobacteria: effects of C8 substitutions on bacterial growth, survival, and resistance","volume":"42","author":"Dong Y","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.661"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1467"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0923-2508(96)80209-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13991"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.42.4.956","article-title":"Killing of Staphylococcus aureus by C\u20108 methoxy fluoroquinolones","volume":"42","author":"Zhao X","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_9_2","volume-title":"Data on file","author":"Bristol\u2010Myers Squibb Pharmaceuticals","year":"1999"},{"key":"e_1_2_1_10_2","volume-title":"Tequin (gatifloxacin) package insert","author":"Bristol\u2010Myers Squibb Pharmaceuticals","year":"1999"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.6.946"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/515104"},{"issue":"6","key":"e_1_2_1_13_2","first-page":"410","article-title":"Refining the fluoroquinolones","volume":"65","author":"Drlica K.","year":"1999","journal-title":"ASM News"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.4.685"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.43.2.410","article-title":"Primary targets of fluoroquinolones in Streptococcus pneumoniae.","volume":"43","author":"Fukuda H","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514923"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.11.3872"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90356-H"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/.61.3.377-392.1997"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.4.447"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00010-3"},{"key":"e_1_2_1_22_2","unstructured":"Torres\u2010VieraC WennerstenCB MoelleringRCJr EliopoulosGM.Comparative in vitro activity of gatifloxacin a new fluoroquinolone antimicrobial against gram\u2010positive bacteria [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.5.645"},{"key":"e_1_2_1_24_2","unstructured":"MinassianB WarrG KolekB RyanB Fung\u2010TomcJ BonnerD.In vitro activity of gatifloxacin against gram\u2010positive aerobic bacteria includingMycobacteriumspp [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_25_2","unstructured":"JohnsonDM JonesRN BiedenbachDJ et al.Comparative antimicrobial activity of gatifloxacin tested againstStreptococcussp; including quality control limits and test method validations [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_26_2","unstructured":"JonesRN PfallerMA DoernGV et al.Antimicrobial activity of gatifloxacin a newer 8\u2010methoxy fluoroquinolone tested against over 23 000 recent clinical isolates from the SENTRY antimicrobial surveillance program 1997 [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_27_2","unstructured":"SchmitzFJ FluitAC JonesME GuptaR AcarJ VerhoefJ.The SENTRY antimicrobial surveillance program was established to monitor the occurrence and antimicrobial susceptibility of bacterial pathogens via an international network of sentinel hospitals [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.10.2108"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.594"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007120"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.639"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00037-1"},{"key":"e_1_2_1_33_2","unstructured":"RolstonKVI LeBlancBM HoDH.In vitro activity of gatifloxacin against gram\u2010positive isolates from cancer patients [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_34_2","unstructured":"BarrigaG AlarconN RojasL PeredoMA.In vitro activity of gatifloxacin and 18 other antibiotics against respiratory tract pathogens [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_35_2","unstructured":"LozaE MorosiniMI NegriMC AlmarazF ReigM BaqueroF.Comparative in vitro activity of gatifloxacin [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_36_2","unstructured":"KishiiR TsurumakiY TakeiM OomoriY HosakaM.Bactericidal activity of gatifloxacin a new 8\u2010methoxy quinolone against quinolone\u2010resistantStaphylococcus aureus[abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00101-1"},{"key":"e_1_2_1_38_2","unstructured":"ThomsonKS MolandES SandersCC.Activity of gatifloxacin against clinical isolates with various levels of resistance to ciprofloxacin [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1475"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","unstructured":"HuczkoE ValeraL ConettaB StickleT MackoA Fung\u2010TomcJ.Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from the clinical trials during the 1997\u201098 period [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999.","DOI":"10.1016\/S0924-8579(00)00223-5"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2299"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.1.103"},{"key":"e_1_2_1_43_2","unstructured":"SaitoH.In vitro activity of gatifloxacin compared with other fluoroquinolones againstMycobacterium tuberculosis[abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1259"},{"key":"e_1_2_1_45_2","unstructured":"MinassianB KolekB WashoT Fung\u2010TomcJ BonnerD.In vitro activity of gatifloxacin against Enterobacteriaceae and non\u2010fermenting gram\u2010negative bacteria [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.2.293"},{"key":"e_1_2_1_47_2","unstructured":"CastilloN BarrigaG AlarconN RojasL PeredoMA.Antibacterial activity of gatifloxacin against Entero\u2010bacteriaceae and nonfermenting gram\u2010negative bacteria [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_48_2","unstructured":"RolstonKVI LeBlancBM HoDH.In vitro activity of gatifloxacin against gram\u2010negative isolates from cancer patients [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1128\/JCM.37.6.1999-2002.1999","article-title":"Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E\u2010test comparisons, and quality control guidelines for H. influenzae.","volume":"37","author":"Jones RN","year":"1999","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_50_2","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/AAC.42.11.2956","article-title":"Activities of new fluoroquinolones against fluoroquinolone\u2010resistant pathogens of the lower respiratory tract","volume":"42","author":"Piddock LJV","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00114-X"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050312"},{"key":"e_1_2_1_53_2","unstructured":"SchubertS UllmanU.Activity of gatifloxacin trovafloxacin ciprofloxacin imipenem meropenem and gentamicin againstSalmonellaspp andAcinetobacterspp [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1128\/AAC.42.9.2459","article-title":"Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms","volume":"42","author":"Ednie LM","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_55_2","unstructured":"HuczkoE KolekB WashoT MinassianB BonnerD Fung\u2010TomcJ.In vitro activity of gatifloxacin against anaerobes Mycoplasma Ureaplasma andChlamydiaspp [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","unstructured":"ErwinME JonesRN BarrettMS PfallerMA HaywardCL DoernGV.Comparative antimicrobial activity of gatifloxacin a new 8\u2010methoxyfluoroquinolone tested againstCampylobacter jejuniand anaerobic bacteria [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998.","DOI":"10.2165\/00128413-199811590-00019"},{"key":"e_1_2_1_57_2","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1128\/AAC.43.11.2783","article-title":"In vitro activities of gatifloxacin, two other quinolones, and five non\u2010quinolone antimicrobials against obligately anaerobic bacteria","volume":"43","author":"Schaumann R","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199500492-00012"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.631"},{"key":"e_1_2_1_60_2","unstructured":"WexlerHM MolitorisD FinegoldSM.In vitro activity of gatifloxacin against anaerobic bacteria isolated from pulmonary specimens [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00150-3"},{"key":"e_1_2_1_62_2","unstructured":"RoblinPM HammerschlagMR.In vitro activity of a new fluoroquinolone gatifloxacin againstChlamydia pneumoniaeandChlamydia trachomatis[abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.672"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.875"},{"key":"e_1_2_1_65_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.41.6.1331","article-title":"In vitro and in vivo activities of AM\u20101155, a new fluoroquinolone, against Chlamydia spp","volume":"41","author":"Miyashita N","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.295"},{"key":"e_1_2_1_67_2","unstructured":"Fung\u2010TomcJ MinassianB DenbleykerK BonnerD.Test factor effects on gatifloxacin antibacterial inhibitory (MIC) and bactericidal (MBC) activities [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_68_2","unstructured":"GradelskiE KolekB Fung\u2010TomcJ MinassianB BonnerD.Activity of gatifloxacin in combination with other antibiotics [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1128\/AAC.43.10.2574","article-title":"Postantibiotic effects of gatifloxacin against gram\u2010positive and \u2010negative organisms","volume":"43","author":"Pankuch GA","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1310"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907223410403"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01793570"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07322-4"},{"key":"e_1_2_1_74_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.43.2.302","article-title":"ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.","volume":"43","author":"Varon E","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00022a013"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.8.1187"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1086"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2650"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.175.22.7363-7372.1993"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1732"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1404-1406.2000"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199500492-00006"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2622"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-42-3-214"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1223-1228.2000"},{"key":"e_1_2_1_86_2","unstructured":"StahlbergHJ GoehlerK GuillaumeM MignotA.Pharmacokinetics of the R\u2010 and S\u2010enantiomers of gatifloxacin a new fluoroquinolone antibiotic following single oral doses to healthy Caucasian volunteers [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_87_2","unstructured":"GraselaD ChristofaloB LacretaF KolliaG DuncanG NoveckR.Single\u2010dose safety and pharmacokinetics of oral gatifloxacin in subjects with hepatic impairment [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_88_2","unstructured":"StahlbergHJ GoehlerK GuillaumeM MignotA.Population pharmacokinetics of gatifloxacin in adults with acute bacterial exacerbations of chronic bronchitis (ACECB) [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_89_2","unstructured":"LaCretaF KaulS KolliaG DuncanG RandallD GraselaD.Bioequivalence of 400\u2013mg intravenous and oral gatifloxacin in healthy adult subjects [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_90_2","unstructured":"LaCretaF KolliaG DuncanG BehrD StoltzR GraselaD.Effect of a high\u2010fat meal on the bioavailability of gatifloxacin in healthy volunteers [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_91_2","unstructured":"GoehlerK StahlbergHJ GuillaumeM MignotA.Safety tolerance and food effect after single and multiple oral doses of gatifloxacin a new fluoroquinolone antibiotic to healthy Caucasian volunteers [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy Toronto Ontario Canada September 28October 1 1997."},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2635"},{"key":"e_1_2_1_93_2","unstructured":"ShibaK SakamotoM SaitoA et al.Effect of ferrous sulfate tea and milk on absorption of AM\u20101155 a 6\u2010fluoro\u20108\u2010methoxy quinolone in humans [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy San Francisco September 1720 1995."},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958040-00010"},{"key":"e_1_2_1_95_2","unstructured":"GraselaD LacretaF UdermanH KolliaG BirkhoferM.A dose\u2010escalation study of the safety tolerance and pharmacokinetics of intravenous gatifloxacin in healthy adult subjects [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_96_2","unstructured":"NaberCK SteghafnerM Kinzig\u2010SchippersM et al.Gatifloxacin: plasma and urine concentrations and penetration into prostatic and seminal fluid after single oral administration in volunteers [abstr]. Presented at the 21st international congress of chemotherapy Birmingham United Kingdom July 47 1999."},{"key":"e_1_2_1_97_2","first-page":"353","article-title":"Penetration of AM\u20101155 into female genital tissues [abstr]","volume":"6","author":"Kaneko T","year":"1995","journal-title":"Can J Infect Dis"},{"key":"e_1_2_1_98_2","unstructured":"WiseR AndrewsJM AshbyJP MarshallG.The pharmacokinetics and penetration of gatifloxacin into an inflammatory exudate after oral administration [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2650"},{"key":"e_1_2_1_100_2","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.40.12.2756","article-title":"Uptake and intracellular activity of AM\u20101155 in phagocytic cells","volume":"40","author":"Yamamoto T","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1067"},{"key":"e_1_2_1_102_2","unstructured":"StahlbergHJ GohlerK LeclercV MignotA.The effect of varying degrees of renal impairment on the pharmacokinetics and safety of gatifloxacin [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1054"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.2.331"},{"key":"e_1_2_1_105_2","first-page":"S34","article-title":"Bactericidal activity of ciprofloxacin against Ps. aeruginosa and other bacteria in an in vitro capillary model","volume":"10","author":"Dudley MN","year":"1988","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_106_2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.1989.00390100083020","article-title":"Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism MIC, and clinical condition on bacterial eradication","volume":"149","author":"Peloquin CA","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_107_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/AAC.40.3.627","article-title":"Twenty\u2010four\u2010hour area under the concentration\u2010time curve\/MIC ratio as a generic predictor or fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model","volume":"40","author":"Maderas\u2010Kelly KJ","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_108_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/AAC.40.3.701","article-title":"Pharmacodynamics of once\u2010 or twice\u2010daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet\u2010fibrin clots","volume":"40","author":"Palmer SM","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2702"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.483"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_2_1_112_2","unstructured":"VostrovS FirsovA LubenkoI KononenkoO ZinnerS PortnoyY.Predictors of quinolone antimicrobial effects in an in vitro dynamic model: the pharmacodynamics of ciprofloxacin and gatifloxacin and trovafloxacin withStaphylococcus aureus[abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.79"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.79"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.521"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.suppl_1.45"},{"key":"e_1_2_1_118_2","first-page":"S1","article-title":"Antibacterial resistance among lower respiratory tract pathogens","volume":"14","author":"Rodvold KA.","year":"1999","journal-title":"J Crit Illness"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_1_120_2","unstructured":"AmbrosePG GraselaDM.Effect of pharmacokinetic and microbiological variability on the pharmacodynamics of gatifloxacin and levofloxacin againstS. pneumoniae[abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.1"},{"key":"e_1_2_1_122_2","volume-title":"Cipro (ciprofloxacin) package insert","author":"Bayer Corporation","year":"1997"},{"key":"e_1_2_1_123_2","volume-title":"Levaquin (levofloxacin) package insert","author":"Ortho\u2010McNeil Pharmaceutical","year":"2000"},{"key":"e_1_2_1_124_2","volume-title":"Avelox (moxifloxacin) package insert","author":"Bayer Corporation","year":"1999"},{"key":"e_1_2_1_125_2","first-page":"S11","article-title":"Treating acute, uncomplicated bacterial sinusitis with gatifloxacin","volume":"20","author":"Sisniega JAL","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_126_2","first-page":"S17","article-title":"Gatifloxacin vs clarithromycin in the management of acute sinusitis","volume":"20","author":"Fogarty C","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_127_2","first-page":"S23","article-title":"Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis","volume":"20","author":"DeAbate CA","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_128_2","first-page":"S30","article-title":"Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: clinical trial results","volume":"20","author":"Ramirez A","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_129_2","unstructured":"SaitoA SoejimaR.The first comparative study with levofloxacin: a double\u2010blind comparative study of gatifloxacin a new quinolone and levofloxacin in pneumonia [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_130_2","first-page":"S49","article-title":"Treating community\u2010acquired pneumonia with once\u2010daily gatifloxacin vs once\u2010daily levofloxacin","volume":"20","author":"Sullivan JG","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_131_2","first-page":"S60","article-title":"Treating community\u2010acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone\/clarithromycin","volume":"20","author":"Fogarty C","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_132_2","first-page":"S40","article-title":"Treating community\u2010acquired pneumonia with once\u2010daily gatifloxacin vs twice\u2010daily clarithromycin","volume":"20","author":"Ramirez JA","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_133_2","unstructured":"TarshisG MiskinBM JonesTM et al.Oral gatifloxacin 400 mg QD vs. oral levofloxacin 500 mg QD in the treatment of uncomplicated skin and soft tissue infections [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_134_2","unstructured":"CoxCC MarburyTC PittmanWG et al.A multicenter comparison of gatifloxacin 400 mg QD vs. ciprofloxacin 500 mg BID in the treatment of complicated urinary tract infection and pyelonephritis [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_135_2","unstructured":"MathewCP RichardGA KirsteinJM et al.Single and multiple dose gatifloxacin in the treatment of acute uncomplicated urinary tract infections in women [abstr]. In: Program and abstracts of the 37th annual meeting of the Infectious Disease Society of America Philadelphia November 1821 1999."},{"key":"e_1_2_1_136_2","unstructured":"StonerBP DouglasJM MartinDH et al.Single\u2010dose gatifloxacin (400 mg or 600 mg) vs. single\u2010dose ofloxacin (400 mg) in the treatment of uncomplicated gonococcal infections [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"issue":"11","key":"e_1_2_1_137_2","first-page":"S70","article-title":"Safety and tolerability of gatifloxacin, an advanced\u2010generation 8\u2010methoxy fluoroquinolone","volume":"20","author":"Breen J","year":"1999","journal-title":"J Respir Dis"},{"key":"e_1_2_1_138_2","first-page":"375","volume-title":"The quinolones","author":"Stahlmann R","year":"1998"},{"key":"e_1_2_1_139_2","unstructured":"FergusonJ McEwenJ GoehlerK.A double\u2010blind placebo\u2010and positive\u2010controlled randomized study to investigate the phototoxic potential of gatifloxacin a new fluoroquinolone antibiotic [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy San Diego September 2427 1998."},{"key":"e_1_2_1_140_2","first-page":"528","article-title":"QTc prolongation and polymorphic ventricular tachycardia in association with levofloxacin","volume":"107","author":"Samaha FF.","year":"1999","journal-title":"Am J Med"},{"key":"e_1_2_1_141_2","first-page":"S41","article-title":"Clinical safety profile of newer fluoroquinolones: how these drugs vary within the class and compare to older agents","volume":"14","author":"Rodvold KA.","year":"1999","journal-title":"J Crit Illness"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.suppl_D.31"},{"issue":"6","key":"e_1_2_1_143_2","first-page":"43S","article-title":"Toxicologic evaluation of ofloxacin","volume":"87","author":"Davis GH","year":"1989","journal-title":"Am J Med"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.1.272"},{"key":"e_1_2_1_145_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2173"},{"issue":"5","key":"e_1_2_1_146_2","first-page":"S1096","article-title":"Inhibition of norfloxacin absorption by antacids and sucralfate","volume":"11","author":"Nix DE","year":"1989","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2436"},{"key":"e_1_2_1_148_2","unstructured":"ShibaK KuaajimaH MomoK.The effects of aluminum hydroxide cimetidine ferrous sulfate green tea and milk on pharmacokinetics of gatifloxacin in healthy humans [abstr]. Presented at the 21st international congress of chemotherapy Birmingham United Kingdom July 47 1999."},{"key":"e_1_2_1_149_2","unstructured":"LaCretaFP KaulS KolliaGD DuncanG RandallDM GraselaDM.Pharmacokinetics of gatifloxacin in combination with ferrous sulfate or calcium carbonate in healthy volunteers [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_150_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3565(25)22834-8","article-title":"Use of midazolam as a human cytochrome P4503A probe. 1. In vitro\u2010in vivo correlation in liver transplant patients","volume":"271","author":"Thummel KE","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_151_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.330.34878"},{"key":"e_1_2_1_152_2","volume-title":"A study to assess the potential for inhibition of cytochrome P4503A4\u2010catalyzed testosterone 6\u03b2\u2010hydroxylase activity by the test substance BMS\u2010206584. Data on file","author":"Bristol\u2010Myers Squibb Co.","year":"1998"},{"key":"e_1_2_1_153_2","unstructured":"StahlbergHJ GohlerK GuillaumeM MignotA.Effects of gatifloxacin on the pharmacokinetics of theophylline in healthy young volunteers [abstr]. Presented at the 21st international congress of chemotherapy Birmingham United Kingdom July 47 1999."},{"key":"e_1_2_1_154_2","unstructured":"NikiY HashiguchiK MiyashitaN et al.Effect of AM\u20101155 on serum concentrations of theophylline [abstr]. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy New Orleans September 1518 1996."},{"key":"e_1_2_1_155_2","unstructured":"OlsenSJ UdermanHD KaulS et al.Lack of interaction between concomitantly administered gatifloxacin and digoxin [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_156_2","unstructured":"GraselaD LacretaF KolliaG RandallD StoltzR BergerS.Lack of effect of multiple\u2010dose gatifloxacin on oral glucose tolerance glucose and insulin homeostasis and glyburide pharmacokinetics in patients with type II non\u2010insulin\u2010dependent diabetes mellitus [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy San Francisco September 2629 1999."},{"key":"e_1_2_1_157_2","volume-title":"Drug topics red book","author":"Cardindale V","year":"2000"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.1.35.34440","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.1.35.34440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:50:13Z","timestamp":1761065413000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.1.35.34440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1592\/phco.21.1.35.34440"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.1.35.34440","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}